The health care and biotechnology sector in Australia represents a diverse range of companies, from major players in pharmaceuticals and biotechnology to smaller medical device and life sciences companies. Listing on the Australian Securities Exchange (ASX) provides companies access to capital from Australia's large investment pool and visibility to investors, customers, and partners. Recent initial public offerings have raised substantial funds for companies in sectors such as health care facilities, biotechnology, and medical technology. The top 100 health care and biotechnology stocks on the ASX represent a variety of country origins and sectors within this industry.
This document provides a directory of drug manufacturers with contact information including telephone numbers and websites. It lists over 100 pharmaceutical companies along with their medical information phone numbers and websites in order to help readers who have questions about medications to contact the manufacturers directly. The goal is to provide this information to help readers who have questions or want to report side effects of drugs they are taking.
The document provides descriptions of various Australian companies operating in the health care equipment and services industry. It describes companies that manufacture medical devices and equipment, provide health care services and facilities, develop health care software, distribute pharmaceutical and medical products, and conduct research in areas like wound healing and biotechnology.
Health Care Equipment and Services - Australian Shares ScanShare Trading
The document provides an overview of various Australian companies operating in the health care equipment and services sector, including their principal activities. Some of the companies mentioned include Ansell Limited which manufactures gloves and protective products, Cochlear Limited which manufactures implantable hearing solutions, and Ramsay Health Care which operates private hospitals in Australia, Indonesia and the UK.
This document lists the top 10 pharmaceutical mergers and acquisitions deals by deal value from 2008-2009. Roche acquired Genentech for $37.4 billion, the largest deal. Novartis acquired Alcon for $10.4 billion, while Takeda acquired Millennium Pharmaceuticals for $8.8 billion, which has closed. Teva Pharmaceutical acquired Barr Pharmaceuticals for $7.46 billion, and Eli Lilly acquired ImClone Systems for $6.5 billion, which has also closed.
- Anteo Diagnostics received the 2015 Frost & Sullivan Asia Pacific Technology Innovation Award for its Mix&Go technology.
- During the quarter, Anteo forged new relationships and partnerships with industry partners including The University of Queensland, Luminex Systems, POC1, IMRA America, Scienion, and Qiagen to further develop and commercialize its Mix&Go technology.
- Anteo launched a new 200nm magnetic particle coupling kit, extended its relationship with Sigma-Aldrich to include its Mix&Go products in their catalog, filed a new patent related to energy applications of its technology, and established a new subsidiary called Anteo Energy to pursue opportunities in the energy sector.
1) Anteo Diagnostics will partner with Atomo Diagnostics to develop a rapid blood test for early detection of heart attacks using Anteo's coating technology and Atomo's AtomoRapid platform.
2) Atomo received $100,000 in funding from the Advance Queensland Johnson & Johnson Innovation QuickFire Challenge to create a proof of concept for their rapid heart attack test.
3) If the proof of concept is successful, Atomo and Anteo will consider fully commercializing an AtomoRapid-based cardiac troponin test, which could improve on current tests in the large and growing $350 million point-of-care cardiac biomarkers market.
The document discusses a conductive polymer binder developed at LBNL that can be used in silicon anode lithium-ion batteries. Silicon offers a much higher theoretical capacity than traditional graphite anodes, but its large volume changes during charging/discharging can lead to capacity fading. The novel binder is flexible and conductive, allowing it to tightly bind silicon nanoparticles and maintain electrical contact through the volume changes. This overcomes challenges facing silicon anodes and enables their use in applications like electric vehicles to significantly increase energy density. The technology has potential for commercialization and competition with other companies working on silicon anode solutions.
This document provides a directory of drug manufacturers with contact information including telephone numbers and websites. It lists over 100 pharmaceutical companies along with their medical information phone numbers and websites in order to help readers who have questions about medications to contact the manufacturers directly. The goal is to provide this information to help readers who have questions or want to report side effects of drugs they are taking.
The document provides descriptions of various Australian companies operating in the health care equipment and services industry. It describes companies that manufacture medical devices and equipment, provide health care services and facilities, develop health care software, distribute pharmaceutical and medical products, and conduct research in areas like wound healing and biotechnology.
Health Care Equipment and Services - Australian Shares ScanShare Trading
The document provides an overview of various Australian companies operating in the health care equipment and services sector, including their principal activities. Some of the companies mentioned include Ansell Limited which manufactures gloves and protective products, Cochlear Limited which manufactures implantable hearing solutions, and Ramsay Health Care which operates private hospitals in Australia, Indonesia and the UK.
This document lists the top 10 pharmaceutical mergers and acquisitions deals by deal value from 2008-2009. Roche acquired Genentech for $37.4 billion, the largest deal. Novartis acquired Alcon for $10.4 billion, while Takeda acquired Millennium Pharmaceuticals for $8.8 billion, which has closed. Teva Pharmaceutical acquired Barr Pharmaceuticals for $7.46 billion, and Eli Lilly acquired ImClone Systems for $6.5 billion, which has also closed.
- Anteo Diagnostics received the 2015 Frost & Sullivan Asia Pacific Technology Innovation Award for its Mix&Go technology.
- During the quarter, Anteo forged new relationships and partnerships with industry partners including The University of Queensland, Luminex Systems, POC1, IMRA America, Scienion, and Qiagen to further develop and commercialize its Mix&Go technology.
- Anteo launched a new 200nm magnetic particle coupling kit, extended its relationship with Sigma-Aldrich to include its Mix&Go products in their catalog, filed a new patent related to energy applications of its technology, and established a new subsidiary called Anteo Energy to pursue opportunities in the energy sector.
1) Anteo Diagnostics will partner with Atomo Diagnostics to develop a rapid blood test for early detection of heart attacks using Anteo's coating technology and Atomo's AtomoRapid platform.
2) Atomo received $100,000 in funding from the Advance Queensland Johnson & Johnson Innovation QuickFire Challenge to create a proof of concept for their rapid heart attack test.
3) If the proof of concept is successful, Atomo and Anteo will consider fully commercializing an AtomoRapid-based cardiac troponin test, which could improve on current tests in the large and growing $350 million point-of-care cardiac biomarkers market.
The document discusses a conductive polymer binder developed at LBNL that can be used in silicon anode lithium-ion batteries. Silicon offers a much higher theoretical capacity than traditional graphite anodes, but its large volume changes during charging/discharging can lead to capacity fading. The novel binder is flexible and conductive, allowing it to tightly bind silicon nanoparticles and maintain electrical contact through the volume changes. This overcomes challenges facing silicon anodes and enables their use in applications like electric vehicles to significantly increase energy density. The technology has potential for commercialization and competition with other companies working on silicon anode solutions.
This document provides an overview of Anteo Diagnostics and their nanotechnology applications. Anteo has developed a patented nanoglue technology called Mix&Go that can bind biological molecules to synthetic surfaces. They are applying this technology in four business areas: 1) in vitro diagnostics and life sciences markets, 2) bioseparations, 3) medical devices, and 4) batteries. For each area, Anteo's nanoglue can improve functionality, sensitivity, and cost efficiency. The document outlines Anteo's revenue generation process, partnership achievements, and the vast potential of their drop-in nanotechnology.
Anteo Diagnostics to acquire Global Diagnostics Company - DiasourceMatt Sanderson
- Anteo Diagnostics will acquire DIAsource ImmunoAssays SA, a global specialty diagnostics company based in Belgium, for €15.4 million plus an earn-out of up to €7.3 million.
- DIAsource generated €11.9 million in revenue in 2014 and €7.2 million in the first half of 2015, with quarterly EBITDA margins of 20%.
- The acquisition will provide Anteo with DIAsource's established global distribution network, manufacturing capabilities, and expanded product range, transitioning Anteo to a cash flow positive business.
Anteo Diagnostics has agreed revised terms to acquire DIAsource ImmunoAssays for the originally announced price of €15.4M. The purchase price will now be paid 50% upfront in cash (€7.7M) and the remaining 50% (€7.7M) via a deferred payment plan over 4 years at 8% annual interest. Anteo will fund the upfront payment through proceeds from a recent capital raising of $13.2M. The deferred payments can be converted to Anteo shares at the vendors' election at a 20% discount to market price. The acquisition builds Anteo's IVD business and the revised terms provide ongoing participation for the vendors in Anteo's future.
Disruptive technology from Anteo Technologies for Lateral Flow testing. New product launching at AACC Conference July 2016. Five times improvement in sensitivity
The document discusses novel methods and materials for downstream processing and bioseparation. It describes several new affinity tags that can be used to facilitate protein purification, including Mix&GoTM glue which provides a simple method for attaching proteins to magnetic particles, environment-responsive matrices that allow temperature-dependent protein adsorption and release, and novel fusion tags like Fh8 and CotB1p that enable calcium-dependent or silica-based purification respectively. The document also outlines new stationary phases, techniques, and instruments for downstream processing like single-use technology, stirred-well filtration, and simulated moving bed chromatography.
The document describes the development of a multiplex panel to measure protein levels of HK2, PKM2, and LDHA in frozen tumor biopsies. Antibodies specific to these proteins were coupled to Luminex beads. Recombinant proteins were used to develop sandwich immunoassays and as calibrators. Sample handling procedures generated cytosolic and mitochondrial fractions from tumor tissues. The panel demonstrated proof-of-concept for monitoring PKM2 levels in cancer cell lines treated with PKM2 inhibitors in vitro.
DCN Diagnostics offers OEM development services for complete lateral flow diagnostic systems. They have expertise in assay development, product engineering, manufacturing process development and commercialization assistance. Their services include reagent development, assay design, reader integration, design of plastic cassettes and cartridges, and manufacturing transfer. DCN has experience across various industries like medical diagnostics, veterinary, food testing, and can develop qualitative or quantitative lateral flow assays.
Lateral flow assays are the most robust, mature immuno sensor available today. Performance in some applications has historically been limited by difficulties in multiplexing and quantification. Novel approaches have been developed and commercialized in recent years that allow for the development and manufacturing of highly multiplexed arrays in lateral flow assays. The patented Symbolics (tm) approach is one such methodology. Symboics (tm) allows for the creation of arrays in lateral flow fields that develop evenly, allowing in turn for the creation of highly complex features such as letters and symbols and also allows for creation of multiplex assays with advanced features such as internal controls. This presentation introduces the principles of multiplexed arraying and the Symbolics technology
Achieving 5 x More Sensitivity And Less Variation In Results Than Covalent Ch...Anteo Technologies
A new method of conjugating antibodies to particles was compared to covalent conjugation in a lateral flow assay for human Chorionic Gonadotropin (hCG).
Anteo Technologies has launched a new Lateral Flow Coupling Kit that contains Anteo’s patented Activation Reagent with all necessary buffers for conjugating antibodies to a range of particles used for lateral flow applications.
In this paper, we demonstrate the performance advantages of using activated magnetic particles, only requiring the addition of antibody solution and blocking. Keeping all other variables constant, this kit was directly compared to covalently (EDAC chemistry) conjugated magnetic particles of the same type using visual detection as the readout.
In this hCG study, this coupling kit achieves five times more sensitivity than the covalently conjugated magnetic particle based assay using half the amount of antibody.
Presentation given at the Garage Start Digital Health Startup Workshop sponsored by ABRT Venture Capital. Content focuses on the healthtech investment landscape.
This presentation summarizes diagnostic services and healthcare strategies for effective performance. It discusses key drivers in the Indian diagnostic industry like foreign health insurance, relaxation in regulations, and emerging technologies. It profiles two major diagnostic service providers - Thyrocare Laboratories and Piramal Diagnostics. The presentation also analyzes in-house diagnostic services provided by Asian Heart Institute and Fortis Healthcare. It discusses their product offerings, pricing, promotion strategies, processes, and people. Lastly, it proposes strategies like focusing on patients, credibility, expertise, and accessibility to improve performance in the fragmented and competitive diagnostic market in India.
This document provides information about the Food and Drug Administration (FDA). It discusses that the FDA is a federal agency that regulates food, drugs, medical devices, and other products to protect public health. The FDA has approximately 9,000 employees including scientists, inspectors, and medical doctors. It is organized into several program centers responsible for approving products and ensuring safety. The document outlines the FDA's role in regulating key areas like food, drugs, medical devices, vaccines, and more.
The document describes the growth and development of Apollo Hospitals from 1983 to present. It discusses how Apollo Hospitals started as a 150 bed hospital in Chennai in 1983 with a mission to provide affordable, high quality healthcare. It has since expanded to become one of the largest healthcare networks in India, operating hospitals, clinics, pharmacies, and other facilities across the country and internationally. The document highlights Apollo Hospitals' use of cutting edge technology and focus on clinical excellence to provide a wide range of specialized healthcare services to millions of patients.
The document describes the growth and development of Apollo Hospitals from 1983 to present. It discusses how Apollo Hospitals started as a 150 bed hospital in Chennai in 1983 with a mission to provide affordable, high quality healthcare. It has since expanded to become one of the largest healthcare networks in India, operating over 300 hospitals and clinics across the country as well as in the Middle East and Southeast Asia. Apollo Hospitals has introduced numerous medical innovations and technologies first in India. It is recognized for clinical excellence and providing world-class healthcare to millions of patients.
A Comparative Study Of Regulatory Registration Procedure Of Nutraceuticals IN...Avinash sharma
This document presents a comparative study of the regulatory registration procedures for nutraceuticals in India, Canada, and Australia. It provides an overview of the relevant regulatory bodies and acts that govern nutraceuticals in each country. In India, nutraceuticals are regulated by the Food Safety and Standards Authority of India under the Food Safety and Standards Act. In Canada, they are defined as natural health products under the Natural Health Products Directorate. And in Australia, they are referred to as complementary medicines and regulated by various acts and standards organizations. The study reviews literature on nutraceutical definitions, types, markets and regulations in these three countries.
Dr. sridhar rudravarapu invited speech- apitco pharmexcil -9 aug 2011Sridhar Rudravarapu
The presentation deliberated on the emerging market opportunities for the local pharma industries to focus on formulations for preventive health care & maintenance. Specific proposals were made for the Hyderabad pharma cluster to set up Nutraceutical/Health Product Incubation Center for serving the local MSME industry needs.
A complete scenario of Medical Device Industry Of USA and India as well as of some major players. The presentation also highlights the Rules and regulations with respect to the devices and also SWOT analysis of emerging markets
Indian journals indexed in scopus (source list) 14 2019Jagdeep Rahul
This document provides a list of 70 Indian journals that are indexed in Scopus. It includes the journal title, publisher, and ISSN for each journal. The list is part of Group A of the UGC-CARE list as of June 14, 2019. The journals cover a wide range of subjects including medical sciences, engineering, mathematics, social sciences, and more.
This document provides guidelines for the effective and appropriate use of long-acting reversible contraception (LARC) methods. It was developed by the National Collaborating Centre for Women's and Children's Health and commissioned by the National Institute for Health and Clinical Excellence. The document covers copper intrauterine devices (IUDs), the intrauterine system (IUS), progestogen-only injectable contraceptives, and progestogen-only subdermal implants. It provides recommendations on the use, effectiveness, risks and benefits of these LARC methods.
The Therapeutic Goods Administration (TGA) regulates therapeutic goods in Australia to protect public health and safety. It evaluates medicines and medical devices to ensure they are safe, effective and of high quality before being supplied in Australia. The TGA is part of the Australian Government Department of Health and has approximately 750 staff from various scientific, medical and administrative backgrounds. It undertakes pre-market evaluations, licenses manufacturers, monitors the market post-approval and maintains the Australian Register of Therapeutic Goods which lists all approved medicines and devices. Higher risk products undergo a rigorous approval process while lower risk goods follow a streamlined listing process.
This document provides an overview of Anteo Diagnostics and their nanotechnology applications. Anteo has developed a patented nanoglue technology called Mix&Go that can bind biological molecules to synthetic surfaces. They are applying this technology in four business areas: 1) in vitro diagnostics and life sciences markets, 2) bioseparations, 3) medical devices, and 4) batteries. For each area, Anteo's nanoglue can improve functionality, sensitivity, and cost efficiency. The document outlines Anteo's revenue generation process, partnership achievements, and the vast potential of their drop-in nanotechnology.
Anteo Diagnostics to acquire Global Diagnostics Company - DiasourceMatt Sanderson
- Anteo Diagnostics will acquire DIAsource ImmunoAssays SA, a global specialty diagnostics company based in Belgium, for €15.4 million plus an earn-out of up to €7.3 million.
- DIAsource generated €11.9 million in revenue in 2014 and €7.2 million in the first half of 2015, with quarterly EBITDA margins of 20%.
- The acquisition will provide Anteo with DIAsource's established global distribution network, manufacturing capabilities, and expanded product range, transitioning Anteo to a cash flow positive business.
Anteo Diagnostics has agreed revised terms to acquire DIAsource ImmunoAssays for the originally announced price of €15.4M. The purchase price will now be paid 50% upfront in cash (€7.7M) and the remaining 50% (€7.7M) via a deferred payment plan over 4 years at 8% annual interest. Anteo will fund the upfront payment through proceeds from a recent capital raising of $13.2M. The deferred payments can be converted to Anteo shares at the vendors' election at a 20% discount to market price. The acquisition builds Anteo's IVD business and the revised terms provide ongoing participation for the vendors in Anteo's future.
Disruptive technology from Anteo Technologies for Lateral Flow testing. New product launching at AACC Conference July 2016. Five times improvement in sensitivity
The document discusses novel methods and materials for downstream processing and bioseparation. It describes several new affinity tags that can be used to facilitate protein purification, including Mix&GoTM glue which provides a simple method for attaching proteins to magnetic particles, environment-responsive matrices that allow temperature-dependent protein adsorption and release, and novel fusion tags like Fh8 and CotB1p that enable calcium-dependent or silica-based purification respectively. The document also outlines new stationary phases, techniques, and instruments for downstream processing like single-use technology, stirred-well filtration, and simulated moving bed chromatography.
The document describes the development of a multiplex panel to measure protein levels of HK2, PKM2, and LDHA in frozen tumor biopsies. Antibodies specific to these proteins were coupled to Luminex beads. Recombinant proteins were used to develop sandwich immunoassays and as calibrators. Sample handling procedures generated cytosolic and mitochondrial fractions from tumor tissues. The panel demonstrated proof-of-concept for monitoring PKM2 levels in cancer cell lines treated with PKM2 inhibitors in vitro.
DCN Diagnostics offers OEM development services for complete lateral flow diagnostic systems. They have expertise in assay development, product engineering, manufacturing process development and commercialization assistance. Their services include reagent development, assay design, reader integration, design of plastic cassettes and cartridges, and manufacturing transfer. DCN has experience across various industries like medical diagnostics, veterinary, food testing, and can develop qualitative or quantitative lateral flow assays.
Lateral flow assays are the most robust, mature immuno sensor available today. Performance in some applications has historically been limited by difficulties in multiplexing and quantification. Novel approaches have been developed and commercialized in recent years that allow for the development and manufacturing of highly multiplexed arrays in lateral flow assays. The patented Symbolics (tm) approach is one such methodology. Symboics (tm) allows for the creation of arrays in lateral flow fields that develop evenly, allowing in turn for the creation of highly complex features such as letters and symbols and also allows for creation of multiplex assays with advanced features such as internal controls. This presentation introduces the principles of multiplexed arraying and the Symbolics technology
Achieving 5 x More Sensitivity And Less Variation In Results Than Covalent Ch...Anteo Technologies
A new method of conjugating antibodies to particles was compared to covalent conjugation in a lateral flow assay for human Chorionic Gonadotropin (hCG).
Anteo Technologies has launched a new Lateral Flow Coupling Kit that contains Anteo’s patented Activation Reagent with all necessary buffers for conjugating antibodies to a range of particles used for lateral flow applications.
In this paper, we demonstrate the performance advantages of using activated magnetic particles, only requiring the addition of antibody solution and blocking. Keeping all other variables constant, this kit was directly compared to covalently (EDAC chemistry) conjugated magnetic particles of the same type using visual detection as the readout.
In this hCG study, this coupling kit achieves five times more sensitivity than the covalently conjugated magnetic particle based assay using half the amount of antibody.
Presentation given at the Garage Start Digital Health Startup Workshop sponsored by ABRT Venture Capital. Content focuses on the healthtech investment landscape.
This presentation summarizes diagnostic services and healthcare strategies for effective performance. It discusses key drivers in the Indian diagnostic industry like foreign health insurance, relaxation in regulations, and emerging technologies. It profiles two major diagnostic service providers - Thyrocare Laboratories and Piramal Diagnostics. The presentation also analyzes in-house diagnostic services provided by Asian Heart Institute and Fortis Healthcare. It discusses their product offerings, pricing, promotion strategies, processes, and people. Lastly, it proposes strategies like focusing on patients, credibility, expertise, and accessibility to improve performance in the fragmented and competitive diagnostic market in India.
This document provides information about the Food and Drug Administration (FDA). It discusses that the FDA is a federal agency that regulates food, drugs, medical devices, and other products to protect public health. The FDA has approximately 9,000 employees including scientists, inspectors, and medical doctors. It is organized into several program centers responsible for approving products and ensuring safety. The document outlines the FDA's role in regulating key areas like food, drugs, medical devices, vaccines, and more.
The document describes the growth and development of Apollo Hospitals from 1983 to present. It discusses how Apollo Hospitals started as a 150 bed hospital in Chennai in 1983 with a mission to provide affordable, high quality healthcare. It has since expanded to become one of the largest healthcare networks in India, operating hospitals, clinics, pharmacies, and other facilities across the country and internationally. The document highlights Apollo Hospitals' use of cutting edge technology and focus on clinical excellence to provide a wide range of specialized healthcare services to millions of patients.
The document describes the growth and development of Apollo Hospitals from 1983 to present. It discusses how Apollo Hospitals started as a 150 bed hospital in Chennai in 1983 with a mission to provide affordable, high quality healthcare. It has since expanded to become one of the largest healthcare networks in India, operating over 300 hospitals and clinics across the country as well as in the Middle East and Southeast Asia. Apollo Hospitals has introduced numerous medical innovations and technologies first in India. It is recognized for clinical excellence and providing world-class healthcare to millions of patients.
A Comparative Study Of Regulatory Registration Procedure Of Nutraceuticals IN...Avinash sharma
This document presents a comparative study of the regulatory registration procedures for nutraceuticals in India, Canada, and Australia. It provides an overview of the relevant regulatory bodies and acts that govern nutraceuticals in each country. In India, nutraceuticals are regulated by the Food Safety and Standards Authority of India under the Food Safety and Standards Act. In Canada, they are defined as natural health products under the Natural Health Products Directorate. And in Australia, they are referred to as complementary medicines and regulated by various acts and standards organizations. The study reviews literature on nutraceutical definitions, types, markets and regulations in these three countries.
Dr. sridhar rudravarapu invited speech- apitco pharmexcil -9 aug 2011Sridhar Rudravarapu
The presentation deliberated on the emerging market opportunities for the local pharma industries to focus on formulations for preventive health care & maintenance. Specific proposals were made for the Hyderabad pharma cluster to set up Nutraceutical/Health Product Incubation Center for serving the local MSME industry needs.
A complete scenario of Medical Device Industry Of USA and India as well as of some major players. The presentation also highlights the Rules and regulations with respect to the devices and also SWOT analysis of emerging markets
Indian journals indexed in scopus (source list) 14 2019Jagdeep Rahul
This document provides a list of 70 Indian journals that are indexed in Scopus. It includes the journal title, publisher, and ISSN for each journal. The list is part of Group A of the UGC-CARE list as of June 14, 2019. The journals cover a wide range of subjects including medical sciences, engineering, mathematics, social sciences, and more.
This document provides guidelines for the effective and appropriate use of long-acting reversible contraception (LARC) methods. It was developed by the National Collaborating Centre for Women's and Children's Health and commissioned by the National Institute for Health and Clinical Excellence. The document covers copper intrauterine devices (IUDs), the intrauterine system (IUS), progestogen-only injectable contraceptives, and progestogen-only subdermal implants. It provides recommendations on the use, effectiveness, risks and benefits of these LARC methods.
The Therapeutic Goods Administration (TGA) regulates therapeutic goods in Australia to protect public health and safety. It evaluates medicines and medical devices to ensure they are safe, effective and of high quality before being supplied in Australia. The TGA is part of the Australian Government Department of Health and has approximately 750 staff from various scientific, medical and administrative backgrounds. It undertakes pre-market evaluations, licenses manufacturers, monitors the market post-approval and maintains the Australian Register of Therapeutic Goods which lists all approved medicines and devices. Higher risk products undergo a rigorous approval process while lower risk goods follow a streamlined listing process.
Merial is a world-leading animal health company created through a joint venture in 1997 between Merck and Sanofi-Aventis. It has over 5,000 employees operating in more than 150 countries, with sales of $2.2 billion in 2006. Merial focuses on developing innovative products and solutions to enhance animal health, well-being, and performance through its nine R&D centers and 16 industrial operations sites worldwide.
Ed holmes - Clinical Research in Singapore - IPPOSI 2010ipposi
Singapore has developed a strategic plan to build its clinical research capabilities and become a leader in translational and clinical research in Asia. Key aspects of the plan include establishing academic medical centers through hospital-medical school partnerships, awarding grants to attract clinician-scientists, developing infrastructure like tissue banks and imaging centers, and focusing research on diseases relevant to Asia through large-scale programs in five strategic disease areas. The goal is to strengthen Singapore's position as a preferred location for early phase clinical trials in Asia.
Australia Nutritional Supplements Market Sample Report 2022 to 2030Insights10
By 2030, it is anticipated that the Australian nutritional and supplements market will reach a value of $9.81 Bn from $4.58 Bn in 2022, growing at a CAGR of 10% during 2022-30.
This document provides information about the Medical Design Excellence Awards (MDEA), including categories of medical products being judged, judging criteria, award winners in various categories, and event sponsors and organizers. It highlights award-winning products like the t:slim insulin pump, AccuVein vein illumination system, and Acessa system for treating uterine fibroids. It also lists the jurors for the 2013 awards and suppliers that contributed to awarded products.
The document outlines guidelines from the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) regarding the use of animals for experimentation. It discusses the goals of CPCSEA which are to promote humane treatment of animals used in research. It provides information on the committee members, forms used, roles of institutional animal ethics committees, and guidelines regarding animal housing, transportation, healthcare, and procurement.
Indian journal indexed in scopus (source list) 31st august 2019Neeraj Gupta
This document provides a list of Indian journals that are indexed in Scopus. It includes the journal title, publisher, ISSN, and E-ISSN for each journal. There are a total of 169 journals listed, which are part of Group A of the UGC-CARE List as of August 31, 2019. The list includes journals covering a wide range of subject areas such as medical sciences, engineering, mathematics, social sciences, and more.
The document discusses Israel's life sciences industry, with a focus on medical devices. It notes that the industry is split into two main categories: biotechnology and medical devices, with most venture capital invested in medical devices. It provides statistics on the largest medical device markets and subsectors in Israel. It also highlights that Israel has the largest number of medical device patents per capita in the world and provides a history of Israeli medical device company exits. The document discusses SCP Vitalife, an Israeli medical technology venture capital firm, and provides details on some of its active portfolio companies, including DIR Technologies, Beta-O2 Technologies, Sensible Medical Innovations, Pocared Diagnostics, and Argo Medical.
Similar to ASX Australian Biotech Market cap list (20)
Anteo Technologies - New York presentation 2015Matt Sanderson
- Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in healthcare, life sciences, and other industries.
- Mix&Go is a universal double-sided molecular coating that gently but strongly binds biomolecules to synthetic surfaces, addressing challenges in test miniaturization and cost reduction.
- Anteo's growth strategy includes licensing its intellectual property, expanding its coating technologies and applications, developing product pipelines that demonstrate Mix&Go's uses, exploring new market opportunities, and acquiring synergistic assets.
The third edition of the EvaluateMedTech® World Preview reveals that the global medtech market is expected to grow at 5% annually between 2013 and 2020, reaching $514 billion in sales by 2020. In vitro diagnostics is projected to remain the largest device area with $71.6 billion in sales in 2020. Johnson & Johnson is currently forecast to be the market leader in 2020, but this could change if Medtronic's acquisition of Covidien is completed, making Medtronic the new leader. The report also finds increasing M&A activity, venture financing, and IPOs in the medtech industry.
Discussing advances in Magnetic Bead coating technologies - Page 9 & 10 - Article from Joshua Soldo from Australian listed Biotech company Anteo Diagnostics ASX:ADO
This document discusses high sensitivity cardiac troponin assays and their clinical applications. It summarizes that high sensitivity troponin assays can measure troponin levels in 50-100% of healthy individuals, allowing for monitoring of baseline troponin levels and detection of deteriorating cardiac conditions. These novel assays may become important tools for predicting patient risk of future adverse cardiac events and guiding preventative treatment adjustments. The document also reviews the biology and genetics of cardiac troponins, classification of troponin assay sensitivities, and use of troponin testing to diagnose acute myocardial infarction.
An Australian biotechnology company called Anteo Diagnostics Limited develops, manufactures, and commercializes proprietary surface coatings called Mix&Go for applications in healthcare and life sciences. Mix&Go forms ultrathin layers that strongly bond biomolecules without damaging their activity. This has applications in diagnostics tests and bioseparations. Anteo is targeting large markets exceeding $50 billion and expects to sign deals with 10 or more companies in the next four years to grow its business.
Anteo Diagnostics ASX Spotlight Presentation March 2014Matt Sanderson
Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in diagnostics and life sciences. In 2013, Anteo achieved solid commercial progress including partnership agreements that are enhancing the prospects of becoming cash flow positive in 2014. Anteo is now focused on advancing near-term opportunities to generate licensing fees and royalties from Mix&Go and expanding into the large market for bioseparations.
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...rightmanforbloodline
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
2024 HIPAA Compliance Training Guide to the Compliance OfficersConference Panel
Join us for a comprehensive 90-minute lesson designed specifically for Compliance Officers and Practice/Business Managers. This 2024 HIPAA Training session will guide you through the critical steps needed to ensure your practice is fully prepared for upcoming audits. Key updates and significant changes under the Omnibus Rule will be covered, along with the latest applicable updates for 2024.
Key Areas Covered:
Texting and Email Communication: Understand the compliance requirements for electronic communication.
Encryption Standards: Learn what is necessary and what is overhyped.
Medical Messaging and Voice Data: Ensure secure handling of sensitive information.
IT Risk Factors: Identify and mitigate risks related to your IT infrastructure.
Why Attend:
Expert Instructor: Brian Tuttle, with over 20 years in Health IT and Compliance Consulting, brings invaluable experience and knowledge, including insights from over 1000 risk assessments and direct dealings with Office of Civil Rights HIPAA auditors.
Actionable Insights: Receive practical advice on preparing for audits and avoiding common mistakes.
Clarity on Compliance: Clear up misconceptions and understand the reality of HIPAA regulations.
Ensure your compliance strategy is up-to-date and effective. Enroll now and be prepared for the 2024 HIPAA audits.
Enroll Now to secure your spot in this crucial training session and ensure your HIPAA compliance is robust and audit-ready.
https://conferencepanel.com/conference/hipaa-training-for-the-compliance-officer-2024-updates
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
Unlocking the Secrets to Safe Patient Handling.pdfLift Ability
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
R3 Stem Cell Therapy: A New Hope for Women with Ovarian FailureR3 Stem Cell
Discover the groundbreaking advancements in stem cell therapy by R3 Stem Cell, offering new hope for women with ovarian failure. This innovative treatment aims to restore ovarian function, improve fertility, and enhance overall well-being, revolutionizing reproductive health for women worldwide.
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...Ear Solutions (ESPL)
Binaural hearing using two hearing aids instead of one offers numerous advantages, including improved sound localization, enhanced sound quality, better speech understanding in noise, reduced listening effort, and greater overall satisfaction. By leveraging the brain’s natural ability to process sound from both ears, binaural hearing aids provide a more balanced, clear, and comfortable hearing experience. If you or a loved one is considering hearing aids, consult with a hearing care professional at Ear Solutions hearing aid clinic in Mumbai to explore the benefits of binaural hearing and determine the best solution for your hearing needs. Embracing binaural hearing can lead to a richer, more engaging auditory experience and significantly improve your quality of life.
The best massage spa Ajman is Chandrima Spa Ajman, which was founded in 2023 and is exclusively for men 24 hours a day. As of right now, our parent firm has been providing massage services to over 50,000+ clients in Ajman for the past 10 years. It has about 8+ branches. This demonstrates that Chandrima Spa Ajman is among the most reasonably priced spas in Ajman and the ideal place to unwind and rejuvenate. We provide a wide range of Spa massage treatments, including Indian, Pakistani, Kerala, Malayali, and body-to-body massages. Numerous massage techniques are available, including deep tissue, Swedish, Thai, Russian, and hot stone massages. Our massage therapists produce genuinely unique treatments that generate a revitalized sense of inner serenely by fusing modern techniques, the cleanest natural substances, and traditional holistic therapists.
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdfDr Rachana Gujar
The "Comprehensive Rainy Season Advisory: Safety and Preparedness Tips" offers essential guidance for navigating rainy weather conditions. It covers strategies for staying safe during storms, flood prevention measures, and advice on preparing for inclement weather. This advisory aims to ensure individuals are equipped with the knowledge and resources to handle the challenges of the rainy season effectively, emphasizing safety, preparedness, and resilience.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
At Apollo Hospital, Lucknow, U.P., we provide specialized care for children experiencing dehydration and other symptoms. We also offer NICU & PICU Ambulance Facility Services. Consult our expert today for the best pediatric emergency care.
For More Details:
Map: https://cutt.ly/BwCeflYo
Name: Apollo Hospital
Address: Singar Nagar, LDA Colony, Lucknow, Uttar Pradesh 226012
Phone: 08429021957
Opening Hours: 24X7
Pediatric Emergency Care for Children | Apollo Hospital
ASX Australian Biotech Market cap list
1. Health Care & Biotechnology
Sector Profile
Overview
The listed Health Care sector represents a diverse range of companies including major Australian success stories in pharmaceuticals,
biotechnology, medical practice and pathology operators, as well as junior life sciences and medical device companies. The large cap end
of the spectrum features well-known names such as CSL, Resmed, Cochlear and Ansell, as well as health care operators such as Sonic,
Primary and Ramsay. The smaller cap end of the sector largely consists of junior biotechnology and medical device companies in various
stages of research, development and commercialisation as well as suppliers to the health care industry.
Reasons to list Health
Care & Biotechnology
companies on ASX
• Access to capital:
– A global market with a wide range of
institutional and retail investors
– Australia has the world’s third largest
pool of investment fund assets*
• Visibility: with investors, customers and
business partners
• Peer Group: list alongside key industry
players
• Opportunities for SMEs: a broad service
offering for early stage and mature
companies
* Source: Investment Company Institute, Q4, 2014
Recent IPOs
ASX
CODE
COMPANY NAME SECTOR* LISTING
DATE
MARKET
CAPITALISATION
ON LISTING (A$ M)
CAPITAL
RAISED
(A$ M)
LEAD
MANAGER/S
HSO Healthscope Ltd Health Care Providers Services 28-Jul-14 $3,637.4 $2,255.2 Macquarie, UBS
REG Regis Healthcare Ltd Health Care Providers Services 07-Oct-14 $1,096.3 $485.9 Macquarie
EHE Estia Health Ltd Health Care Providers Services 05-Dec-14 $1,040.1 $725.0 UBS, Deutsche Bank,
Morgan Stanley
OHE Orion Health Group Ltd Health Care Technology 26-Nov-14 $820.0 $112.0 Deutsche Craigs, First NZ
PSQ Pacific Smiles Group Ltd Health Care Providers Services 21-Nov-14 $197.6 $42.1 CBA Equities
GSS Genetic Signatures Ltd Life Sciences Tools Services 31-Mar-15 $28.0 $7.5 Lodge Corporate
OCC Orthocell Ltd Biotechnology 12-Aug-14 $22.1 $8.0 KTM Capital, Azure
Capital
ANR Anatara Lifesciences Ltd Biotechnology 16-Oct-14 $10.0 $7.0 Wilson HTM
PYL Phytotech Medical Ltd Pharmaceuticals 22-Jan-15 $6.9 $5.9 BBY
PIQ Proteomics International
Laboratories Ltd
Life Sciences Tools Services 16-Apr-15 $3.6 $3.1 KS Capital
* Source: Bloomberg
SP/ASX 200 SP/ASX 300 Health Care SP/ASX 300 Pharma Biotech
SP/ASX 300 Health Care Equipment Services
0
100
200
300
400
500
600
700
IndexLevel
SP/ASX 200 v Health Care Indices
Source: Bloomberg, May 2015
Jan05
Jul05
Jan06
Jul06
Jan07
Jul07
Jan08
Jul08
Jan09
Jul09
Jan10
Jul10
Jan11
Jul11
Jan12
Jul12
Jan13
Jul13
Jan14
Jul14
Jan15
2. Health Care Biotechnology Fact Sheet
Top 100 Stocks
ASX COMPANY MARKET SECTOR^ COUNTRY OF
CODE NAME CAPITALISATION INCORPORATION^
(A$ M)^
CSL CSL Ltd 41,250.3 Biotechnology Australia
RHC Ramsay Health Care Ltd 12,900.9 Health Care Facilities Australia
RMD Resmed Inc 9,920.9 Health Care Equipment United States
SHL Sonic Healthcare Ltd 7,746.4 Health Care Services Australia
HSO Healthscope Ltd 4,763.3 Health Care Facilities Australia
COH Cochlear Ltd 4,518.0 Health Care Equipment Australia
ANN Ansell Ltd 3,955.6 Health Care Supplies Australia
FPH Fisher Paykel Healthcare Corporation Ltd 3,230.7 Health Care Equipment New Zealand
PRY Primary Health Care Ltd 2,672.9 Health Care Services Australia
REG Regis Healthcare Ltd 1,718.0 Health Care Facilities Australia
SRX Sirtex Medical Ltd 1,514.4 Biotechnology Australia
EBO EBOS Group Ltd 1,384.8 Health Care Distributors New Zealand
MSB Mesoblast Ltd 1,253.8 Biotechnology Australia
EHE Estia Heatlh Ltd 1,170.3 Health Care Facilities Australia
SIP Sigma Pharmaceuticals Ltd 923.9 Health Care Distributors Australia
MYX Mayne Pharma Group Ltd 891.8 Pharmaceuticals Australia
API Australian Pharmaceutical Industries Ltd 883.5 Health Care Distributors Australia
GXL Greencross Ltd 787.4 Health Care Facilities Australia
JHC Japara Healthcare Ltd 731.3 Health Care Facilities Australia
SNZ Summerset Group Holdings Ltd 711.7 Health Care Facilities New Zealand
OHE Orion Health Group Ltd 688.8 Health Care Technology New Zealand
VRT Virtus Health Ltd 561.9 Health Care Facilities Australia
UNS Unilife Corporation 496.0 Health Care Supplies United States
NAN Nanosonics Ltd 492.3 Health Care Supplies Australia
CAJ Capitol Health Ltd 483.4 Health Care Services Australia
MVF Monash IVF Group Ltd 345.5 Biotechnology Australia
PSQ Pacific Smiles Group Ltd 325.3 Health Care Facilities Australia
IPD ImpediMed Ltd 255.2 Health Care Equipment Australia
SPL Starpharma Holdings Ltd 252.1 Pharmaceuticals Australia
PME Pro Medicus Ltd 220.6 Health Care Technology Australia
BNO Bionomics Ltd 173.5 Biotechnology Australia
RVA Reva Medical, Inc 171.3 Health Care Equipment United States
ONT 1300 Smiles Ltd 155.1 Health Care Facilities Australia
ACR Acrux Ltd 153.2 Pharmaceuticals Australia
NEU Neuren Pharmaceuticals Ltd 142.8 Life Sciences Tools Services New Zealand
PVA Psivida Corp 142.6 Life Sciences Tools Services United States
MVP Medical Developments International Ltd 139.7 Pharmaceuticals Australia
AHZ Admedus Ltd 138.4 Health Care Supplies Australia
CUV Clinuvel Pharmaceuticals Ltd 136.8 Biotechnology Australia
LHC Lifehealthcare Group Ltd 133.1 Health Care Distributors Australia
SOM Somnomed Ltd 129.4 Health Care Equipment Australia
VEI Vision Eye Institute Ltd 127.1 Health Care Facilities Australia
NRT Novogen Ltd 125.5 Pharmaceuticals Australia
OSP Osprey Medical Inc 100.1 Health Care Equipment United States
OBJ OBJ Ltd 97.4 Pharmaceuticals Australia
BLT Benitec Biopharma Ltd 91.5 Biotechnology Australia
VLA Viralytics Ltd 90.2 Biotechnology Australia
PHG Pulse Health Ltd 83.8 Health Care Facilities Australia
VSC Vita Life Sciences Ltd 82.0 Pharmaceuticals Australia
PXS Pharmaxis Ltd 81.8 Pharmaceuticals Australia
PBT Prana Biotechnology Ltd 81.7 Biotechnology Australia
CYP Cynata Therapeutics Ltd 71.4 Biotechnology Australia
ADO Anteo Diagnostics Ltd 70.1 Life Sciences Tools Services Australia
SDI SDI Ltd 65.4 Health Care Supplies Australia
3DM 3D Medical Ltd 65.2 Health Care Supplies Australia
GTG Genetic Technologies Ltd 61.7 Life Sciences Tools Services Australia
GID GI Dynamics, Inc 61.7 Health Care Equipment United States
SVA Simavita Ltd 59.0 Health Care Equipment Canada
3. UBI Universal Biosensors Inc. 53.6 Health Care Equipment United States
IDT IDT Australia Ltd 51.6 Pharmaceuticals Australia
AZV Azure Healthcare Ltd 51.2 Health Care Equipment Australia
PRR Prima Biomed Ltd 50.5 Biotechnology Australia
CMP Compumedics Ltd 39.2 Health Care Equipment Australia
ELX Ellex Medical Lasers Ltd 38.2 Health Care Equipment Australia
ACG Atcor Medical Holdings Ltd 37.4 Health Care Equipment Australia
OSL Oncosil Medical Ltd 35.6 Life Sciences Tools Services Australia
GSS Genetic Signatures Ltd 35.4 Life Sciences Tools Services Australia
DVL Dorsavi Ltd 34.1 Biotechnology Australia
PGC Paragon Care Ltd 33.8 Health Care Distributors Australia
BIT Biotron Ltd 33.5 Biotechnology Australia
PNV Polynovo Ltd 33.5 Biotechnology Australia
GBI Genera Biosystems Ltd 33.3 Biotechnology Australia
BRC Brain Resource Ltd 32.1 Health Care Services Australia
AVH Avita Medical Ltd 31.9 Biotechnology Australia
SUD Suda Ltd 31.8 Pharmaceuticals Australia
POH Phosphagenics Ltd 31.5 Pharmaceuticals Australia
CLV Clover Corporation Ltd 31.4 Health Care Supplies Australia
OCC Orthocell Ltd 30.9 Biotechnology Australia
MEB Medibio Ltd 29.6 Biotechnology Australia
CGS Cogstate Ltd 28.9 Health Care Technology Australia
ISN Isonea Ltd 28.2 Health Care Equipment Australia
ANR Anatara Lifesciences Ltd 27.9 Biotechnology Australia
RGS Regeneus Ltd 27.2 Biotechnology Australia
PYC Phylogica Ltd 27.1 Biotechnology Australia
IIL Innate Immunotherapeutics Ltd 26.7 Biotechnology Australia
CYC Cyclopharm Ltd 26.4 Health Care Equipment Australia
ACU Acuvax Ltd 25.8 Biotechnology Australia
LCT Living Cell Technologies Ltd 25.4 Biotechnology Australia
RNO Rhinomed Ltd 25.4 Pharmaceuticals Australia
AJJ Asian American Medical Group Ltd 23.9 Health Care Services Virgin Islands (British)
CIR Circadian Technologies Ltd 23.7 Biotechnology Australia
TIS Tissue Therapies Ltd 20.3 Biotechnology Australia
ACL Alchemia Ltd 20.1 Biotechnology Australia
ITD ITL Ltd 19.5 Health Care Supplies Australia
ANP Antisense Therapeutics Ltd 19.4 Pharmaceuticals Australia
CDY Cellmid Ltd 19.1 Biotechnology Australia
PAA Pharmaust Ltd 18.2 Pharmaceuticals Australia
CTE Cryosite Ltd 17.8 Life Sciences Tools Services Australia
IVX Invion Ltd 17.3 Pharmaceuticals Australia
RHT Resonance Health Ltd 16.5 Health Care Equipment Australia
* Ranked by market capitalisation 21 May 2015
^ Bloomberg
Value Traded – SP/ASX 200 Health Care Index
Source: Bloomberg, May 2015
A$billion
Jan05
Jul05
Jan06
Jul06
Jan07
Jul07
Jan08
Jul08
Jan09
Jul09
Jan10
Jul10
Jan11
Jul11
Jan12
Jul12
Jan13
Jul13
Jan14
Jul14
Jan15
0
1
2
3
4
5
6
7
8